A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Rosuvastatin (a Sensitive BCRP Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Osimertinib (Primary) ; Rosuvastatin (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 17 Jan 2018 Planned End Date changed from 4 Jan 2018 to 31 Dec 2018.
- 05 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jan 2018.
- 07 Jun 2016 Results from this trial and other trial (NCT02197234)presented at the 52nd Annual Meeting of the American Society of Clinical Oncology